CliffBio
small molecule

ZONISADE

ZONISAMIDE

Loss of exclusivityAugust 2038latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameZONISADE
Active ingredientZONISAMIDE
Strength100MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2022
Marketing statusRX

Listed patents

PatentExpiresType
11478456August 2038use U-3458
12491179August 2038product
11529333August 2038product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZONISADE patent cliff — loss of exclusivity August 2038 | CliffBio